Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.00
100% from low
Exchange
OTC Link
OS
Borrow rate
6.66%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $167.7K | $353.7K | $353.7K | $353.7K | $353.7K | $353.7K | $353.7K | $353.4K |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $1.5K | $0 | $0 |
| Gross profit | $121.1K | $353.7K | $353.7K | $353.7K | $353.7K | $352.3K | $353.7K | $0 |
| Gross margin | 72.2% | 100.0% | 100.0% | 100.0% | 100.0% | 99.6% | 100.0% | 0.0% |
| R&D | $709.3K | $2.2M | $819.4K | $1.1M | $624.0K | $526.4K | $112.9K | $0 |
| Operating income | −$2.7M | −$2.9M | −$1.3M | −$2.3M | −$1.4M | −$1.4M | −$360.0K | $237.8K |
| EBITDA | −$2.7M | −$3.0M | −$1.6M | −$4.1M | −$736.0K | −$1.4M | −$359.5K | $237.8K |
| Net income | −$2.8M | −$3.0M | −$1.6M | −$4.1M | −$743.0K | −$312.0K | −$97.3K | −$401.6K |
| Net margin | -1660.5% | -849.3% | -446.7% | -1151.4% | -210.0% | -88.2% | -27.5% | -113.6% |
| EPS (diluted) | -0.13 | -0.13 | -0.06 | -0.13 | -0.02 | -0.01 | -0.00 | -0.01 |
Annual figures · source: Financial Modeling Prep
0913693 B.C. LTD
No one on the platform currently holds REPCF.
No tracked institution reports a position in REPCF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2016-08-10 | 1-for-10reverse |
No one on the platform has traded REPCF yet.
| $2565 |
| — |
| NMLSFRestart Life Sciences Corp. | $0.01 | -87.93% | $438605 | — |
| PKTXProtoKinetix, Incorporated | $0.01 | -13.56% | $2M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.0× sales vs its 12.0× historical median P/S.
Fair value ≈ $0.06 · price $0.00 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.